Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Inspiration Healthcare Group in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 29.40.
Current Consensus is
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Inspiration Healthcare Group. This N/A consensus rating has held steady for over two years.
Inspiration Healthcare Group plc, together with its subsidiaries, supplies medical technology for critical care, operating theatre, and home healthcare applications worldwide. The company provides SLE6000, a technology for little lungs; LifeStart, a bedside resuscitation unit; First Breath, a neonatal non-invasive support; Inspire rPAP, a 2-piece non-invasive system for the resuscitation of infants; Genedrive MT-RNR1 system, a care genetic test used to detect mitochondrial gene MT-RNR1 in human buccal cells; Unique+ cerebral function monitoring (CFM) used to help in the diagnosis of brain injury; and push-to-set intermittent, paediatric intermittent, neonatal intermittent, and 2-Mode Continuous regulators, as well as Ohio medical MRI compatible vacuum regulators. It offers inspire nCPAP used for treating infants; anatomical face masks; mini stat CO2, stat CO2, and neostat CO2; ALGOPEDOL; and heel warmers products. In addition, the company birdy, a positioning cushions support for infant; traveller RS restraint system for mobile incubators; IncuCap, an incubator and phototherapy; MaviLED phototherapy, a tool in the treatment of neonatal hyperbilirubinemia; FirstBreathTM dual heated breathing circuit; and FirstBreathTM single heated breathing circuit with water trap. Further, it offers Alphacore5 controller; and Viomedex surgical skin markers. Inspiration Healthcare Group plc was founded in 1998 and is based in Croydon, the United Kingdom.
Read More